Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerlapirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 13/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerlapirdine SCHEMBL3534330 | 1.00 | HTR6 (0.71) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| Cerlapirdine SCHEMBL3531794 | 0.99 | HTR6 (0.70) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3534211 | 0.97 | HTR6 (0.67) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3531307 | 0.95 | HTR6 (0.64) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3533745 | 0.92 | HTR6 (0.60) | HTR6PDGFRBPDGFRAHTR2A | |
| Hydrochloric Acid SCHEMBL3528991 | 0.91 | HTR6 (0.59) | HTR6PDGFRBPDGFRAHTR2A | |
| SCHEMBL3529039 | 0.90 | HTR6 (0.58) | HTR6PTPN1 | |
| Hydrochloric Acid SCHEMBL3534727 | 0.90 | HTR6 (0.58) | HTR6PTPN1 | |
| SCHEMBL3532505 | 0.89 | HTR6 (0.56) | HTR6HTR1BHTR2A | |
| SCHEMBL3533813 | 0.88 | HTR6 (0.56) | HTR6HTR1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| WO-2025006553-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024263563-A1 | METABOTROPIC GLUTAMATE SUBTYPE-2 AND -3 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4479365-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | AXOVANT SCIENCES GMBH (CH) | 2022-04-19 | — | — | US | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | HTR6 281/4885PDGFRB 1685/4885PDGFRA 2183/4885 |
| US-11304932-B2 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | HTR2A, HTR5A, HTR1A | HTR6 12/4885PDGFRB 448/4885PDGFRA 364/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | HTR6 159/4885PDGFRB 1918/4885PDGFRA 1369/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | HTR6 2051/4885PDGFRB 2897/4885PDGFRA 3368/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | HTR6 153/4885PDGFRB 1224/4885PDGFRA 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.